UNIVERSIDAD DEL PAIS VASCO Patent applications |
Patent application number | Title | Published |
20150038545 | HYDROXYPHENYL PYRROLE COMPOUNDS CONTAINING AN HYDROXAMIC ACID AS HDAC INHIBITORS AND MEDICINAL APPLICATIONS THEREOF - The present invention refers to compounds derived from hydroxyphenyl 1H-pyrrole rings, which have the following formula (I): | 02-05-2015 |
20130072576 | Cationic Nanogels For Biotechnological Applications - The present invention relates to a biocompatible cationic nanogel comprising a polymer network, said polymer network comprising polymer units interconnected with one another through a cross-linking agent, wherein said polymer network can be obtained by polymerizing N-vinylcaprolactam and a cross-linking agent in a dispersed medium, in the presence of a cationic initiator and a cationic or non-ionic emulsifier. The invention also relates to methods for obtaining the mentioned nanogels as well as to pharmaceutical compositions comprising them. | 03-21-2013 |
20120315480 | COPPER NANOPARTICLES WITH MAGNETIC PROPERTIES - The present invention relates to thiol- or an amine-associated ferromagnetic or superparamagnetic copper nanoparticles with an average diameter less than 30 nm, to the method for obtaining them and their applications in biomedicine and other fields. | 12-13-2012 |
20120183589 | Lipid Nanoparticles For Gene Therapy - The present invention relates to a lipid nanoparticle system comprising a lipid component, a cationic surfactant, a non-ionic surfactant, a polysaccharide and, optionally, a positively charged peptide, useful for the release of pharmacologically active molecules, and especially for transfecting genetic material into cells and/or tissues. It also relates to methods for obtaining nanoparticles, to pharmaceutical compositions comprising it, as well as to the use thereof in gene therapy. | 07-19-2012 |
20120183532 | COMPOUNDS STIMULATING UNDESIRABLE CELLULAR ADHESION AND APPLICATIONS THEREOF - The invention relates to non-glycosylated proteins, based on the Kre9 protein of | 07-19-2012 |
20120093836 | PHARMACEUTICAL COMPOSITIONS FOR TREATING METASTASIS - The present invention relates to the use of an antifungal agent or of a compound capable of binding to a mannoprotein and blocking the binding of said mannoprotein to an endothelial cell receptor, in the preparation of a pharmaceutical composition for treating a disease associated to an unwanted cell adhesion. Likewise, the present invention also contemplates methods aimed at identifying a compound potentially useful for preventing and/or treating a disease associated to an unwanted cell adhesion, for predicting the probability of a patient suffering from cancer to suffer from metastasis and for designing a personalized therapy for a patient suffering from cancer. | 04-19-2012 |
20110212060 | USE OF MICROPARTICLES CONTAINING GENETICALLY MODIFIED CELLS IN THE TREATMENT OF NEURODEGENERATIVE DISEASES - The present invention relates to methods for the treatment of neurodegenerative diseases by means of the use of microparticles comprising genetically modified cells expressing neurotrophic and/or angiogenic factors and wherein said microparticles are administered by means of implantation at the cerebral cortex level. | 09-01-2011 |
20110151458 | METHODS AND REAGENTS FOR THE DETECTION OF SALMONELLA SPP - The invention relates to an in vitro method for the detection of bacteria of the | 06-23-2011 |
20110060038 | NITROGENATED TRANS-STILBENE ANALOGS, METHOD FOR THE OBTENTION AND MEDICAL APPLICATIONS THEREOF - This invention is related to new nitrogenated trans-stilbene compounds, more specifically, imine, pyrrole and indole derivatives, with procedures for the preparation and use thereof as pharmaceutical compositions for the treatment and/or chemoprevention of those mammalian diseases such as cancer, fibrosclerosis and acute/chronic inflammation, graft-versus-host reaction, ischemic-reperfusion tissue injury in stroke and heart attack, neurodegeneration, and during organ transplantation, whose pathogenic and pathophysiological mechanisms depend on or are significantly contributed by undesirable oxidative stress, angiogenic and proliferative responses. | 03-10-2011 |
20100297192 | USE OF MICROPARTICLES FOR VACCINES AND THE RELEASE OF BIOLOGICALLY ACTIVE MOLECULES - The invention relates to microparticles based on a PLGA biodegradable polymer and an alginate polymer which encapsulate immunologically active peptides or proteins. Said microparticles, and the pharmaceutical compositions developed from them and the uses thereof, are applicable to the field of human and animal health as a vaccine and system for releasing biologically active molecules. | 11-25-2010 |
20100285068 | METHOD FOR THE INTERNALIZATION OF NON-INVASIVE BACTERIA IN EUKARYOTE CELLS - The present invention relates to the use of adenylate cyclase toxin (ACT), or a functionally equivalent variant thereof, as an inducing agent for the internalization of non-invasive bacteria in eukaryotic cells. Due to ACT, said non-invasive bacterium can move through the plasma membrane of a eukaryotic cell and transfer plasmid DNA to said cell, which is useful for releasing or introducing molecules of therapeutic interest, for example, antigens, in the interior of the eukaryotic cell, thereby triggering the immune response. | 11-11-2010 |
20100272812 | RGD-MODIFIED ALGINATE MICROPARTICLES AS A DRUG RELEASE SYSTEM - The object of the present invention is to provide particles of a polymeric material containing cells therein, wherein said particles have a strength that is substantially greater than the microcapsules known in the state of the art. Said strength is achieved by means of functionalizing the polymeric material forming the microcapsule with a peptide which can bind to the adhesion proteins of the cell membrane, such that the cells act as cross-linking agents of the matrix resulting in an improvement of the mechanical properties of the matrixes | 10-28-2010 |
20100172990 | BIOCOMPATIBLE MICROGELS AND APPLICATIONS THEREOF - The biocompatible microgels comprises a polymeric network, said polymeric network comprising monomeric units interconnected with one another through a crosslinking agent, wherein said polymeric network can be obtained by polymerization in a dispersed medium of a biocompatible vinyl monomer and a crosslinking agent. The microgel may further comprise a biologically active agent. Said biocompatible microgels can be used, among other applications, to transport and dose biologically active agents. | 07-08-2010 |
20090131339 | COMPOUNDS HAVING NEUROPROTECTIVE PROPERTIES - The invention relates to the use of morin and mangiferin, the pharmaceutically acceptable salts, prodrugs and/or solvates thereof in the production of a pharmaceutical composition for the prevention and/or treatment of a neurodegenerative disease and symptoms associated with ageing, as well as to food compositions comprising said compounds. | 05-21-2009 |
20080318799 | Method of Quantifying the G Protein-Coupled Receptor (Gpcr)/G Protein Coupling Using a Cell Membrane Array - The invention relates to a method for quantifying G protein-coupled receptor (GPCR)-G protein binding by means of using a cell membrane array, which comprises (i) putting an unlabeled candidate compound in contact with a cell membrane array in the presence of labeled GTP or of a labeled, non-hydrolyzable analog thereof, in conditions allowing the interaction between said compound and said GPCR present in said cell membranes, and between said labeled GTP or analog thereof and said G protein present in said membranes; (ii) washing; and (iii) quantifying the signal obtained due to the binding of the labeled GTP (or analog) to said G protein. It is applicable in the analysis of the interaction between compounds and cell membrane receptor proteins and of the intracellular signaling mechanisms triggering this interaction mechanism mediated by said compounds. | 12-25-2008 |
20080249157 | Novel Inhibitors of the Lfa-1/Icam-1 Interaction and Uses Thereof - The invention relates to the treatment of disorders or diseases mediated by LFA-1/ICAM-1 molecular interaction. This is based on the use of novel chemical compounds capable of inhibiting said interaction, and more particularly, to pharmaceutical compositions containing these compounds. | 10-09-2008 |